INTRODUCTION
The prion diseases, which include Creutzfeldt-Jakob disease (CJD) in humans, and scrapie and bovine spongiform encephalopathy (BSE) in animals, are a group of fatal, transmissible, neurodegenerative conditions. The human prion diseases are unique in that they may have a sporadic, inherited or transmitted aetiology (Collinge, 2001) , and there is evidence that BSE-like prions have infected humans (Collinge et al., 1996; Bruce et al., 1997; Hill et al., 1997) . A common feature of all prion diseases is the posttranslational conversion of the normal cellular prion protein (PrP C ), a host-encoded, glycosylphosphotidylinositol (GPI)-anchored sialoglycoprotein (Stahl et al., 1987) , into an abnormal isoform termed PrP Sc (Prusiner, 1991) . There are no known covalent post-translational modifications between PrP C and PrP Sc (Stahl et al., 1993) , the difference between the two being conformational. While PrP C can be completely digested by the serine protease, proteinase K (PK), only 90-100 aa are removed from the N terminus of PrP Sc by PK, depending upon prion strain-type, leaving a large protease resistant C-terminal fragment. Both circular dichroism and Fourier transform infrared spectroscopic methods show PrP C to be rich in a-helix, whereas PrP Sc is predominantly b-sheet (Pan et al., 1993) . It has been postulated that PrP Sc may act as a template promoting the conversion of PrP C into PrP Sc . Using PrP-specific monoclonal antibodies (mAbs), it has been reported that residues 90-120, accessible in PrP C , are largely cryptic in the protease resistant core of PrP Sc ) and only become exposed after denaturation (Peretz et al., 1997) . Using the same mAbs and recombinant Syrian hamster (SHa) PrP , it was suggested that residues 90-115 are involved in the conformational rearrangement of PrP Sc formation (Leclerc et al., 2001) . Similar NMR structures of PrP C have been reported for mouse (Riek et al., 1996) , hamster (James et al., 1997) and human (Hosszu et al., 1999; Zahn et al., 2000) recombinant protein residues~120-231. In vitro studies have shown that PrP can adopt different conformations depending upon solvent pH and redox potential (Swietnicki et al., 1997; Hornemann & Glockshuber, 1998) . At low pH following reduction of the disulphide bond, the folded C-terminal domain of the human prion protein can exist as a soluble monomeric b-sheet structure (Jackson et al., 1999a) . It is possible that the conversion of the a-helical form, a-PrP, to the b-sheet form, b-PrP, caused by reduction and mild acidification is relevant to the conditions that PrP C might encounter within the cell (Shyng et al., 1993) .
Distinct prion strains can be serially propagated, producing characteristic clinical features and neuropathology in defined hosts. Although the molecular basis of strains is unknown, PrP Sc can be distinguished by differing physicochemical properties of the protein (Bessen & Marsh, 1992; Collinge et al., 1996) . After PK digestion of brain homogenates from different CJD clinical phenotypes, variation in PrP Sc fragment length has been observed (Collinge et al., 1996; Parchi et al., 1996) and glycosylation can also be used to further distinguish strains (Collinge et al., 1996) . PrP is post-translationally modified by the addition of two Nlinked glycosylation sites at positions 181 and 197 in the human sequence, either or both of which can be occupied to give monoglycosylated or diglycoslyated isoforms, or remain unglycosylated. The type and combination of sugar molecules can produce a high degree of heterogeneity (Endo et al., 1989) , potentially affecting the conformation and intermolecular interactions. Crucially, both PrP Sc fragment size (Collinge et al., 1996; Telling et al., 1996) and glycoform ratios (Collinge et al., 1996) , following PK cleavage, can be maintained on serial passage in experimental animals, arguing that these intrinsic properties of PrP Sc may encode prion strain diversity. Several human PrP Sc types have been identified that are associated with different phenotypes of CJD . Based both on PrP Sc fragment sizes and the ratios of the three PrP glycoforms, four different PrP Sc types are readily distinguishable (Collinge et al., 1996 Wadsworth et al., 1999; Hill & Collinge, 2002) .
Although all the PrP glycoforms are present in PrP Sc , it is not known if they can be physically or chemically separated, except when denatured, since existing mAbs do not readily immunoprecipitate PrP Sc , i.e. we cannot yet determine whether a single PrP Sc particle contains mixed glycoforms or only a single species. Prnp 0/0 mice have been used by many groups to raise anti-PrP mAbs (Krasemann et al., 1996; Korth et al., 1997; Zanusso et al., 1998; Williamson et al., 1998; Nakamura et al., 2003) , but mAbs that can readily imunoprecipitate PrP Sc or recognize different glycoforms of PrP are rare. We have also used Prnp 0/0 mice to raise antiPrP mAbs, using a soluble a-helical monomer of the human PrP sequence 91-231 (a-PrP 91-231 ) as antigen. We also used the novel immunogen recombinant human b-PrP 91-231 , identical in amino acid sequence but folded into a soluble monomeric conformation and partially resistant to PK (Jackson et al., 1999b) , as antigen and produced mAbs that could efficiently immunoprecipitate PrP Sc . Here, we describe these mAbs and the findings on the physical association of PrP glycoforms in normal and prion-diseased brains. We also show that mAbs raised to b-PrP 91-231 and reactive to residues 93-105, can immunoprecipitate native PrP Sc .
METHODS
mAb production. mAbs were produced in Prnp 0/0 mice (Bueler et al., 1993) back-crossed onto an FVB/N background. Briefly, the mice were immunized subcutaneously with 100 mg human recombinant a-or b-PrP 91-231 (Jackson et al., 1999b) in complete Freund's adjuvant and in incomplete Freund's adjuvant on days 21 and 42, then boosted intraperitoneally on day 50 with 50 mg antigen in PBS. Three days later, single-cell suspensions of mouse splenocytes were prepared and fused with the NS0 myeloma cell line, using conventional methodology. Hybridomas were selected after screening culture supernatants by ELISA against a-and b-PrP , by dot blot against human and mouse brain homogenates and by flow cytometry for recognition of human and mouse PrP C (data not shown). We studied mAbs ICSM-4, ICSM-10 and ICSM-18 that were produced from immunization with a-PrP , and ICSM-35 and ICSM-37 produced from immunization with b-PrP . After affinity purification using protein-A or G-Sepharose column chromatography, the antibodies were isotyped using a panel of anti-mouse Ig subclass-specific mAbs (Pierce). The mAb epitopes were mapped by ELISA, using IgG at 1-2 mg ml 21 and human 20 aa synthetic peptides, spanning the PrP sequence 91-231. Animal care conformed to national and institutional guidelines. Western blotting. The brain homogenates were electrophoresed through 16 % gels using conventional methods. Following transfer onto Immobilon-P membranes (Millipore), non-specific binding was blocked with 5 % (w/v) milk proteins in PBST and ICSM-4, ICSM-10, ICSM-18, ICSM-35 and ICSM-37 optimized at IgG 1-0?5 mg ml
21
, and ICSM-4, ICSM-18 and ICSM-35 also as biotinylated IgG 0?25 mg ml 21 were used as primary antibody. Anti-mouse (Fab) IgG-horseradish peroxidase or streptavidin-horseradish peroxidase (Sigma-Aldrich) was used for detection, and visualized by Supersignal chemiluminescent ECL or ECL-Plus substrate (Pierce) and Kodak Biomax MR film.
The infected and normal brain homogenates were titrated by Western blotting for PrP detection at dilutions from 1 to 0?0001 % (w/v), and for PK digestion at 2-200 mg ml 21 , using ICSM-18. As a negative control, mAbs BRIC-222 (IgG1) raised to CD44, anti-D (IgG1)-antiRh blood group related, and BRIC-126 (IgG2b) raised to CD47 were used (IBGRL).
Immunoprecipitation. Immunoprecipitation was carried out either directly, using antibody covalently cross-linked to beads to capture PrP, or indirectly, using beads to capture antibody-antigen immune complexes. Diseased and normal brain homogenates were used, matched for their PrP signal.
For the direct method, protein-A Dynabeads or M-280 streptavidin beads (Dynal Biotech) were used. Protein-A beads have a maximum binding capacity of mouse IgG 100 mg beads ml 21 (~2?7610 9 beads ml 21 ). For maximum binding, we incubated 100 mg IgG per 100 ml beads, and the immobilized immunoglobulin was cross-linked to the beads using 20 mM dimethyl pimelimidate (Sigma-Aldrich). M-280 streptavidin beads (binding capacity of 50-100 mg biotinylatedIgG ml 21 ) were used with biotinylated mAbs. mAbs IgG were biotinylated by incubating 500 ml IgG (1 mg ml
) with Biotin-LC-NHS ester (2 mg ml 21 ) (IGEN International), at a 1 : 20 molar ratio, and quenching the reaction with 20 ml 2 M glycine. Free biotin was removed using a PD-10 column (Amersham Bioscience). To allow binding of both high and low affinity mAbs, IgG-adsorbed streptavidin or cross-linked protein-A beads (20-25 ml) were incubated with 100-200 ml of 0?5-0?1 % (w/v) brain homogenates for 8-12 h at 4 uC, then washed briefly, 6-8 times in PBST (1 % Tween 20). To determine the PK-resistance of the bead-adsorbed PrP, these beads were treated with PK (20 mg ml 21 for mouse and 50 mg ml 21 for human PrP Sc ), for 1 h at 37 uC, and the reaction was stopped with 20 mM PMSF or AEBSF [4-(2-aminoethyl)-benzenesulphonyl fluoride hydrochloride] (Roche). For a direct capture of PrP 27-30 , the brain homogenates were treated with PK before immunoprecipitation.
The indirect immunoprecipitation method was carried out by incubating anti-PrP mAbs IgG at a concentration of 2-3 mg ml 21 with brain homogenate [200 ml 0?5-0?1 % (w/v)] containing a complete protease inhibitor cocktail (Roche), for 12-14 h at 4 uC; to allow even the weak antibodies to bind. Protein-G Dynabeads (20-25 ml) (Dynal Biotech), with a binding capacity of IgG~200 mg ml 21 , were then added for 2 h at room temperature, to immunoprecipitate the immune complexes. The beads were then washed four times with PBST (2 % Tween 20), four times with PBS containing 2 % Tween 20 and 2 % NP40, and once with PBS to remove the detergents. The captured PrP was visualized by Western blot.
Adsorption of PrP to beads was optimized by varying the incubation time, temperature, adsorption buffer, salt concentration, pH and detergent. Both isotype control negative mAb-and PBS-adsorbed beads were negative when using normal brain, but a small amount of non-specific binding occurred with scrapie-affected brain homogenate that could not be eradicated. Using tosyl-activated Dynabeads (Fischer et al., 2000) did not improve non-specific PrP Sc binding, which occurred at longer film exposures or higher brain homogenate concentrations.
Immunocytochemistry. RML-inoculated mice have minimal brain plaque formation; thus we used terminally scrapie-sick SJL mice, inoculated with mouse passaged-BSE prions, that produced spongiform changes associated with large discrete PrP-reactive plaques (Lloyd et al., 2004) . Age matched PBS-inoculated SJL mice were used as controls.
A standard PrP
Sc detection protocol was used (Bell & Ironside, 1997) . Briefly, formaldehyde (10 %) fixed brains were immersed in 98 % formic acid for 1 h to denature infectious prions. Treated brains were then embedded in paraffin wax and 4 mm sections were cut. These brain sections were autoclaved and treated with formic acid and 4 M guanidine thiocyanate to abolish the PrP C signal. To label PrP Sc , ICSM-4, ICSM-10, ICSM-18 and ICSM-35 were used as primary antibody, followed by avidin-biotin complex, and DAB (39,3-diaminobenzedine) as the chromagen. The staining of PrP was optimized by titrating mAb IgG, using appropriate controls throughout.
RESULTS
Five antibodies were used in this study, all raised to the recombinant PrP purified from Escherichia coli cells. Two conformational isomers of PrP were used as immunogens. One form, which we denote a-PrP, had been refolded in the oxidized state, i.e. with the disulphide bridge intact, and adopts the predominantly a-helical PrP C conformation. The PrP C form of the protein is in the normal cellular conformation and is characterized by being highly sensitive to digestion by PK. The other form, denoted b-PrP, is refolded in the reduced state, i.e. with the disulphide bridge broken. The physical properties of b-PrP share some similarity with ex-vivo PrP Sc . The PrP Sc form of the protein accumulates in prion-infected brain tissue, and is characterized by its resistance to proteolytic degradation by PK.
Three of the five antibodies (ICSM-4, ICSM-10 and ICSM-18) were raised to a-PrP and two (ICSM-35 and ICSM-37) to b-PrP ( Fig. 1a ). ICSM-10 was characterized as binding to both the unglycosylated and monoglycosylated bands, but not the diglycosylated species (Table 1 and Fig. 1a) . Although ICSM-4 and ICSM-10 were negative in the peptide ELISA, their epitopes are likely to span areas around residues 181 and 197, the known sites of N-linked glycosylation of PrP.
The ratio of PrP glycoforms is a consistent feature of different prion strains, which can be differentiated by Western blotting with mAb 3F4 (Wadsworth et al., 2003 (Kanyo et al., 1999) , also recognized all three glycoforms of PrP in the correct proportions in Western blots of human CJD brains, containing PrP Sc types 1-4 (Fig. 1b) . All of the negative control mAbs, as well as the controls in which primary antibody is omitted, were negative (data not shown). Anti-PrP mAbs were also negative when tested against Prnp 0/0 brain homogenates (data not shown).
In wild-type mouse brain homogenate, a truncated PrP band~18 kDa was also recognized by ICSM-4, ICSM-10 and weakly by ICSM-18 and ICSM-37, and a truncated band at 20-22 kDa was recognized in scrapie-infected mouse brain homogenate by all the mAbs (Fig. 1a) . Both the 18 kDa and 20-22 kDa truncated bands were PK-sensitive and, since they were both recognized by ICSM-4, they are probably unglycosylated. A PK-sensitive 18 kDa truncated band (C1) and a PK-resistant 20-22 kDa band (C2) in CJD brain have been reported previously (Chen et al., 1995) , as have minority C-terminal smaller fragments that would not be visualized by the majority of our antibodies with more N-terminal epitopes.
PrP glycoforms are associated in native PrP
Sc but not in PrP C To investigate whether an individual PrP Sc particle in infected brain consists of a single glycoform or a mixture, we used our glycoform-specific mAbs, ICSM-4 and ICSM-10, to capture PK-resistant PrP from infected brain homogenates. The unique properties of ICSM-4 and ICSM-10 allowed the individual PrP glycoforms, which comprise native PrP C , to be selectively captured from homogenates of normal murine brain. ICSM-4 immunoprecipitated a single band corresponding to the unglycosylated form of PrP, whereas ICSM-10 captured two principal bands corresponding to the unglycosylated and monoglycosylated isoforms (Fig. 2a) . In contrast, immunoprecipitation from scrapie-infected homogenates by ICSM-4 and ICSM-10 was either negative or the three PK-resistant PrP glycoforms were only weakly captured (Fig. 2a) . PrP Sc glycoforms could not be separated, regardless of the glycoform specificity of the mAb used. Thus, ICSM-4 and ICSM-10 could selectively immunoprecipitate PrP C glycoforms from normal brain homogenates, whereas PrP Sc glycoforms always co-immunoprecipitated as a complex from prion-infected brain homogenates. The inability of ICSM-4 to differentially immunoprecipitate PrP Sc glycoforms from infected brains was conditional upon performing the reaction in non-denaturing conditions, as carried out above. If PrP Sc was first denatured by the addition of SDS and then subjected to immunoprecipitation, ICSM-4 captured only the unglycosylated PrP band, although ICSM-18 continued to capture all three PrP glycoforms (Fig. 2b) . Confirmation that PrP Sc was successfully denatured was provided by treating with PK, before and after SDS denaturation: thus PrP Sc was PK-resistant prior to denaturation, whereas once denatured, PrP Sc became sensitive to PK digestion (Fig. 2b) . Despite their ability of recognizing only a subset of the glycoforms, using the direct immunoprecipitaion method, ICSM-4 and to a lesser extent ICSM-10 weakly immunoprecipitated PrP Sc as a complex of all three glycoforms from a vCJD-affected brain homogenate (Fig. 3a) . These immunoprecipitations were very weak, suggesting a very low affinity for mAb-PrP Sc interaction, perhaps involving only a small subset of PrP Sc molecules.
Using the indirect method, ICSM-4 (3 mg ml
21
) only immunoprecipitated a major single band representing unglycosylated PrP C from normal human brain homogenate, whereas in contrast, it weakly immunoprecipitated all three glycoforms comprising PrP 27-30 from PK-treated vCJD-affected brain homogenate (Fig. 3b) . The capture of the three native PrP 27-30 glycoforms was improved when a higher concentration of ICSM-4 IgG (20 mg ml 21 ) was used (Fig. 3c) . The presence of the three intact native PrP [27] [28] [29] [30] glycoforms in the sample was confirmed by their immunoprecipitation by ICSM-35 ( Fig. 3b and c) . In addition, when an aliquot of the same brain homogenate PrP Sc was denatured, ICSM-4 exclusively recognized unglycosylated PrP, while all three PrP glycoforms were present and recognized by ICSM-18 (Fig. 3d) . This confirms that it is association of the three glycoforms of PrP in the quaternary structure of PrP Sc that allows immunoprecipitation of the complex via recognition of only a single component. ICSM-4 has a high affinity for unglycosylated PrP, and it could deplete a 0?1 % (w/v) normal mouse brain homogenate of its unglycosylated PrP C after immunoprecipitation (Fig. 4a) . However, it did not have the same affect in depleting PrP Sc , as immunoprecipitaion by ICSM-4 was so weak that PrP Sc signal from the 0?25 % (w/v) vCJD brain homogenate remained almost unchanged (Fig. 4b) . The weak binding of ICSM-4 to native PrP Sc indicates that its epitope, on the unglycosylated PrP incorporated into the native prion polymer, is partially hidden and revealed as the unglycosylated protein dissociates upon denaturation. It is also possible that ICSM-4 only immunoprecipitates a subset of the PrP Sc polymers, as sequential immunoprecipitaion from the same brain homogenate by ICSM-4 led to subsequently weaker or negative capture of PrP (data not shown). Whatever the explanation, the ICSM-4 to PrP Sc interaction is of low affinity and alternative methods of coupling ICSM-4 to different magnetic beads did not improve its ability to immunoprecipitate PrP Sc (data not shown).
ICSM-18 has a higher affinity for native PrP C than PrP Sc ICSM-18 was raised against the a-conformer of recombinant human PrP 91-231 , which may explain its higher affinity The direct immunoprecipitation method (see Methods) was used, and captured PrP on the beads was either treated with PK (+) or not ("). Captured PrP was eluted from the beads and visualized by Western blot, using ICSM-18 as primary antibody. (b) Immunoprecipitation (IP) of denatured PrP Sc (+SDS), derived from scrapie-affected (Sc) mouse brain homogenate [80 ml of 1 % (w/v)] is shown for negative control (") mAb (BRIC-222), ICSM-4, and positive control mAb ICSM-18. The mAbs were covalently coupled to protein-A beads, and 20 ml of the beads was used in the direct immunoprecipitation method (see Methods). The captured PrP was eluted from the beads, visualized by Western blotting using ICSM-18 as primary antibody. Western blot (WB) of the brain homogenate after PK digestion (+) showed that the PK-resistant native PrP for native PrP C than PrP Sc . We have shown that ICSM-18 strongly binds denatured-PrP derived from both PrP C and PrP Sc (Fig. 1) , and we have also shown that it efficiently immunoprecipitates native PrP C from normal murine brain homogenates, whereas immunoprecipitation of native PrP Sc was weak (Fig. 2) . The immunoprecipitation of native PrP Sc from a vCJD-affected brain homogenate was more successful if PK-treatment was performed after PrP capture (Fig. 3a) rather than before (Fig. 3b) , although ICSM-18 strongly recognizes human denatured PrP 27-30 on a Western blot (Fig. 3d) . It is possible that ICSM-18 may only bind a subset of native PrP Sc .
The high affinity of ICSM-18 for PrP C was demonstrated not only by its strong recognition of native (Fig. 3b) and denatured PrP C (Fig. 4c) , but also by its depletion of native PrP C from a normal human brain homogenate after immunoprecipitation (Fig. 4c) .
Residues 93-105 in PrP
Sc are resistant to proteolysis with PK, but are exposed to antibody binding mAbs raised to b-PrP, such as ICSM-35 and ICSM-37, could immunoprecipitate both native PrP C and PrP Sc . Indeed, ICSM-35 had a higher affinity for native PrP Sc than PrP C , while ICSM-37 had a high affinity for both native PrP C and PrP Sc (Fig. 2a) . ICSM-35 and ICSM-37 immunoprecipitate all three PK-sensitive PrP C and three PK-resistant PrP Sc bands from normal and prion-infected mouse (Fig. 2a) and human brain homogenates (Fig. 3a) . As previously described (Khalili-Shirazi et al., 2005) , we showed by ELISA that these b-PrP-derived mAbs are directed to epitopes comprising residues 93-105 and 97-105 of PrP, which are unstructured in PrP C . The structure of PrP Sc is unknown, but this N-terminal region of PrP Sc is believed to be important in conferring some strain-specific properties of prions, and is thus likely to have at least a degree of conformation that may vary between strains. Structural heterogeneity within the N terminus may explain the different affinities observed for ICSM-35 and ICSM-37, for native PrP C and PrP Sc .
ICSM-35 robustly immunoprecipitated native human PrP Sc regardless of the method used, whether the vCJD brain homogenate was treated with PK after immunocapture (Fig. 3a) or before ( Fig. 3b and c) . Although both ICSM-35 and 3F4 immunoprecipitated native PrP C from normal and vCJD human brain homogenates (Fig. 3b) , ICSM-35 and 3F4 singularly failed to immunoprecipitate PrP Sc at IgG concentrations of 3 mg ml 21 (Fig. 3b) or 20 mg ml 21 (Fig. 3c) . We conclude that residues 93-105 of PrP, comprising the epitope for ICSM-35, are exposed in human and mouse PrP Sc . The efficiency of ICSM-35 binding to native PrP Sc was evidenced by its ability to almost deplete a vCJD brain homogenate (0?25 % w/v) of its PrP Sc signal (Fig. 4b) . The high affinity of ICSM-35 for native PrP Sc was also confirmed, when no measurable dissociation of mouse-scrapie brain-derived PrP Sc was observed from the PrP Sc -bound covalently coupled ICSM-35-protein-A beads, after washing the beads in excess PBST for 12 h at 4 uC (data not shown). A titration of scrapie-affected mouse brain homogenate also showed ICSM-35 capturing PrP Sc from as little as 0?01 % (w/v) brain homogenate (data not shown).
The glycoform profile of PrP
Sc immunoprecipitated by ICSM-35 exactly matched the known glycoform profile of the infected brain. Diglycosylated dominant PrP Sc bands from vCJD-affected brains and monoglycosylated dominant PrP Sc from sporadic CJD-affected brain homogenates were immunoprecipitated by ICSM-35 (Fig. 5) . This suggests that PrP Sc aggregates are highly ordered, and the glycoform ratios specific for each strain are reflected in the prion polymer itself.
Anti-PrP mAbs recognize PrP
Sc plaques in the brain Serial sections of brain from mice infected with mouse passaged-BSE stained with ICSM-4, ICSM-10, ICSM-18 and ICSM-35 (Fig. 6) showed areas of PrP Sc reactive plaques or deposits, particularly in the corpus callosal area of mice inoculated with mouse-passaged BSE (Fig. 6 ). These sections demonstrated classical histological features of spongiform change, consistent with typical prion disease. Age-matched, saline-inoculated controls had normal histology and were negative when tested with these mAbs (data not shown).
The PrP deposits in the brains of mice with terminal prion Sc from vCJD and sporadic CJD brains by ICSM-35. ICSM-35 and negative control (") mAb covalently coupled protein-A beads (30 ml) were used to immunoprecipitate PrP Sc from 300 ml of 0?2 % (w/v) of a human vCJD or a sporadic CJD brain homogenate, using the direct immunoprecipitation method (see Methods). PrP-captured beads were treated with PK (+), PrP 27-30 was eluted from the beads and visualized by Western blotting, using 3F4 mAb as primary antibody. A cartoon of diglycosylated (filled box), monoglycosylated (grey box) and unglycosylated (open box) PrP bands for brain homogenates '+PK' is outlined. 
DISCUSSION
Glycoform-specific mAbs, such as ICSM-4 and ICSM-10, were produced from immunization with a-PrP, a conformation of the prion protein that is PK-sensitive and, thus more easily processed for presentation to B cells than the partially PK-resistant b-PrP (Jackson et al., 1999b Sc , regardless of the mAb used, is an assembly of glycoforms and is homogeneous.
Having shown that PrP
Sc particles in a given prion strain are composed of a characteristic spectrum of glycoforms, it is interesting to consider mechanisms that can account for this observation. With respect to the formation of the PrP Sc particles, there are two mechanisms that can lead to a defined characteristic ratio of components which constitutes a prion strain. In a stoichiometric assembly process, the formation of prion particles occurs by the exact packing of the three glycoforms. For instance, a given PrP conformation and packing arrangement, which constitutes a strain, might only allow direct 2 : 4 : 2 stoichiometry of the three glycoforms, i.e. there is a discreet, whole-number molecular stoichiometry. By contrast, in a statistical or probabilistic process, a strain will be characterized by having different on and off rates for addition of each glycoform to the growing prion particle. For instance, assuming a negligible rate of dissociation, the ratio of the on-rates for each glycoform would exactly reflect the ratio in the assembled prion particle. However, unlike the case of the stoichiometric model, there would not be an exact packing arrangement that only allows precise stoichiometries; rather there would be a given probability of finding a particular glycoform at a particular location in the structure of the fibril.
Studying the appearance of PrP
Sc deposits in the brains of mice with terminal scrapie using our panel of mAbs showed that, regardless of the mAb's glycoform specificity, large PrP-reactive plaques were successfully recognized in the corpus callosum of diseased brain. These brain sections were treated such that native PrP C was destroyed and PrP Sc was denatured; hence, the mAbs should recognize their specific PrP Sc glycoforms if their epitope is available. A higher concentration of ICSM-4 than ICSM-18 or ICSM-35 was required to detect the plaques, possibly reflecting lower unglycosylated PrP expression in the brain or that the [27] [28] [29] [30] , and it was deduced that the 90-120 region is exposed in PrP C but is largely cryptic in PrP 27-30 (Peretz et al., 1997) . In agreement with previous findings, we found that 3F4 could successfully immunoprecipitate human native PrP 27-30 glycoforms from prion-infected human and mouse brain homogenates, indicating that residues 93-105 are not only exposed in native PrP C , but are at least partially also exposed in human and mouse native PrP Sc . In confirmation, five further mAbs that were raised to human b-PrP 91-231 and could readily immunoprecipitate native PrP Sc were also directed to residues 91-105 (unpublished data). The only amino acid difference between SHa and human prion proteins within residues 91-105 is at position 97, with human PrP containing serine (S) and hamster asparagine (N). However, since ICSM-35 and ICSM-37 both successfully capture mouse native PrP 27-30 , which like SHa PrP has an N at amino acid position 97, this should have no bearing on immunoprecipitation of SHa and human native PrP 27-30 . Since there are no amino acid differences between human and SHa PrP at residues 105-112, it remains possible that the difference observed in PrP 27-30 immunoprecipitation by mAbs 3F4, D13, ICSM-35 and ICSM-37 is either due to a strain effect -the conformation of this region being distinct in hamster scrapie -or occluded by another ligand in hamster native PrP [27] [28] [29] [30] . Alternatively, the PrP molecules used to produce 3F4 and to enrich for D13 may not resemble native PrP Sc in this region. In contrast, recombinant b-PrP has proven to be an extremely useful immunogen for raising mAbs with high affinity for native PrP Sc . In view of our findings, we deduce that the region encompassing residues 93-105 is not buried or altered in PrP 27-30 in prion-infected human and mouse brains, and that this region appears to be a highly antigenic epitope for mAbs raised to b-PrP 91-231 .
